Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Net Income (2021 - 2026)

HeartSciences (HSCS) has disclosed Net Income for 5 consecutive years, with -$2.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income fell 11.9% year-over-year to -$2.4 million, compared with a TTM value of -$9.1 million through Oct 2025, down 17.01%, and an annual FY2025 reading of -$8.9 million, down 32.93% over the prior year.
  • Net Income was -$2.4 million for Q4 2025 at HeartSciences, down from -$2.1 million in the prior quarter.
  • Across five years, Net Income topped out at -$752051.0 in Q3 2021 and bottomed at -$2.6 million in Q1 2025.
  • Average Net Income over 5 years is -$1.7 million, with a median of -$1.8 million recorded in 2022.
  • The sharpest move saw Net Income plummeted 109.25% in 2022, then increased 20.55% in 2023.
  • Year by year, Net Income stood at -$1.0 million in 2021, then crashed by 74.7% to -$1.8 million in 2022, then grew by 3.28% to -$1.7 million in 2023, then fell by 20.26% to -$2.1 million in 2024, then decreased by 11.9% to -$2.4 million in 2025.
  • Business Quant data shows Net Income for HSCS at -$2.4 million in Q4 2025, -$2.1 million in Q3 2025, and -$2.1 million in Q2 2025.